Dole (NYSE:DOLE) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.38 by 15.79 percent.
Needham Maintains Buy on Cytokinetics, Lowers Price Target to $58
Needham analyst Serge Belanger maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from $60 to $58.